Drugs / HGS1029
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01013818 | Oct 2009 → Oct 2011 | lymphoid neoplasm | Human Genome Sciences Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00708006 | May 2008 → Dec 2011 | cancer | Human Genome Sciences Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HGS1029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01013818 ↗ |
| Route | Intravenous | “Escalating doses by IV (in the vein)” NCT00708006 ↗ |